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Summary 
Many anti-SARS-CoV-2 neutralizing antibodies target the ACE2-binding site on viral spike 
receptor-binding domains (RBDs). The most potent antibodies recognize exposed variable 
epitopes, often rendering them ineffective against other sarbecoviruses and SARS-CoV-2 
variants. Class 4 anti-RBD antibodies against a less-exposed, but more-conserved, cryptic 
epitope could recognize newly-emergent zoonotic sarbecoviruses and variants, but usually 
show only weak neutralization potencies. We characterized two class 4 anti-RBD antibodies 
derived from COVID-19 donors that exhibited broad recognition and potent neutralization of 
zoonotic coronavirus and SARS-CoV-2 variants. C118-RBD and C022-RBD structures revealed 
CDRH3 mainchain H-bond interactions that extended an RBD b-sheet, thus reducing sensitivity 
to RBD sidechain changes, and epitopes that extended from the cryptic epitope to occlude 
ACE2 binding. A C118-spike trimer structure revealed rotated RBDs to allow cryptic epitope 
access and the potential for intra-spike crosslinking to increase avidity. These studies facilitate 
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Introduction 
The current SARS-CoV-2 pandemic is a crisis of immediate global concern, but two other 
zoonotic betacoronaviruses, SARS-CoV and MERS-CoV (Middle East Respiratory Syndrome), 
also resulted in epidemics within the last 20 years (de Wit et al., 2016). All three viruses likely 
originated in bats (Li et al., 2005; Zhou et al., 2021), with SARS-CoV and MERS-CoV having 
adapted to intermediary animal hosts, most likely palm civets (Song et al., 2005) and dromedary 
camels (Haagmans et al., 2014), respectively, prior to infection of humans. Serological surveys 
of people living near caves where bats carry diverse coronaviruses suggests direct transmission 
of SARS-CoV-like viruses (Wang et al., 2018), raising the possibility of future outbreaks 
resulting from human infection with SARS-like betacoronaviruses (sarbecoviruses).  
 
Coronaviruses encode a trimeric spike glycoprotein (S) that serves as the machinery for fusing 
the viral and host cell membranes (Fung and Liu, 2019). The first step in fusion is contact of S 
with a host receptor. The receptor-binding domains (RBDs) at the apex of the S trimers of 
SARS-CoV-2, SARS-CoV, HCoV-NL63, and some animal coronaviruses utilize angiotensin-
converting enzyme 2 (ACE2) as their receptor (Hoffmann et al., 2020; Li et al., 2003; Zhou et 
al., 2020b). RBDs can adopt either ‘down’ or ‘up’ conformations, with ACE2 binding only 
possible to RBDs in an ‘up’ conformation (Kirchdoerfer et al., 2016; Li et al., 2019; Walls et al., 
2020; Walls et al., 2016; Wrapp et al., 2020; Yuan et al., 2017). A phylogenetic tree of the 
relationship between coronavirus S protein RBDs shows that sarbecovirus RBDs form a 
separate branch (Figure 1A).  
 
Consistent with their obligate role in viral entry, sarbecovirus S trimers are the primary targets of 
neutralizing antibodies (Brouwer et al., 2020; Cao et al., 2020; Fung and Liu, 2019; Kreer et al., 
2020; Liu et al., 2020b; Robbiani et al., 2020; Rogers et al., 2020; Seydoux et al., 2020; Shi et 
al., 2020; Zost et al., 2020b), with many focusing on the RBD (Barnes et al., 2020a; Barnes et 
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al., 2020b; Brouwer et al., 2020; Cao et al., 2020; Kreer et al., 2020; Liu et al., 2020b; Pinto et 
al., 2020; Robbiani et al., 2020; Rogers et al., 2020; Seydoux et al., 2020; Zost et al., 2020a). 
Structural analysis of the binding epitopes of anti-SARS-CoV-2 RBD antibodies enabled their 
classification into four initial categories: class 1, derived from VH3-53/VH3-63 germlines and 
including a short heavy chain complementarity determining region 3 (CDRH3) that bind an 
epitope overlapping with the ACE2 binding site and only recognize ‘up’ RBDs; class 2, whose 
epitope also overlaps with the ACE2 binding site, but which can bind to both ‘up’ and ‘down’ 
RBD conformations; class 3, which bind to the opposite side of ‘up’ and ‘down’ RBDs adjacent 
to an N-glycan attached to residue N343; and class 4, which are often weakly neutralizing 
antibodies that target a cryptic epitope facing the interior of the spike protein on ‘up’ RBDs 
(Barnes et al., 2020a) (Figure S1).  
 
Potent anti-SARS-CoV-2 neutralizing antibodies are typically class 1 or class 2 anti-RBD 
antibodies that block the ACE2 binding site (Barnes et al., 2020a; Dejnirattisai et al., 2021; Lee 
et al., 2021; Liu et al., 2020b; Piccoli et al., 2020a; Tortorici, 2020). Since class 1 and class 2 
RBD epitopes are not well conserved (Figure 1B), antibodies in these classes are unlikely to 
strongly cross-react across sarbecovirus RBDs. However, an in vitro-selected variant of an 
ACE2 blocking antibody isolated from a SARS-infected survivor exhibited increased cross-
reactive properties, showing neutralization of SARS-CoV-2 and other betacoronaviruses 
(Rappazzo et al., 2021). In general, however, as isolated from infected donors, class 3 and 
class 4 RBD-binding antibodies are better prospects for neutralizing across multiple strains and 
thereby potentially protecting against emergent sarbecoviruses. Indeed, S309, a class 3 anti-
RBD antibody isolated from a SARS-CoV–infected donor, demonstrated cross-reactive 
neutralization of SARS-CoV-2 (Pinto et al., 2020).  Furthermore, reports of class 4 human 
antibodies that exhibit cross-reactive binding and neutralization amongst sarbecoviruses (Liu et 
al., 2020a; Starr et al., 2021a; Tortorici et al., 2021) suggest that further investigation of 
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antibodies from COVID-19 convalescent donors could lead to discoveries of potent and broadly 
cross-reactive class 4 antibodies that recognize the highly-conserved, ‘cryptic’ RBD epitope. 
 
Here we investigated C118 and C022, two class 4 human antibodies isolated from COVID-19 
donors (Robbiani et al., 2020) that show breadth of binding and neutralization across 
sarbecoviruses and SARS-CoV-2 variants of concern. We report crystal structures of C118 
complexed with SARS RBD and C022 complexed with SARS-CoV-2 RBD, which revealed 
interactions with a conserved portion of the RBD in common with interactions of previously-
described cross-reactive but more weakly-neutralizing class 4 antibodies; e.g., CR3022 (Huo et 
al., 2020; Yuan et al., 2020a; Yuan et al., 2020b), S304/S2A4 (Piccoli et al., 2020, Cell), and 
EY6A (Zhou et al., 2020a). Unlike these class 4 anti-RBD antibodies, C118 and C022 also 
occlude portions of the ACE2 binding site to facilitate more potent neutralization. A single-
particle cryo-EM structure of a C118-S trimer complex demonstrated binding of C118 to an 
intact trimer, revealing an S configuration with increased separation between the RBDs than 
found in class 1-3 Fab-S or ACE2-S trimer structures, and revealed the potential for intra-spike 
crosslinking. These results define a cross-reactive class 4-like epitope on sarbecovirus RBDs 
that can be targeted in vaccine design and illustrate a mechanism by which the cryptic RBD 




C022 and C118 IgGs recognize and neutralize diverse sarbecoviruses, including SARS-
CoV-2 variants  
From a survey to identify cross-reactive monoclonal antibodies isolated from SARS-CoV-2–
infected donors from the New York area (Robbiani et al., 2020), we found antibodies isolated 
from different donors, C118 (VH3-30/VL4-69-encoded) and C022 (VH4-39/VK1-5-encoded), 
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that recognized a diverse panel of 12 sarbecovirus RBDs spanning clades 1, 1/2, 2 and 3 
(Figure 1). As evaluated by enzyme-linked immunosorbent assay (ELISA), C118 bound to 
RBDs from all sarbecoviruses tested, and C022 bound to all but two RBDs, similar to the class 4 
anti-RBD antibody CR3022 (Figure 1C). By comparison, the cross-reactive class 3 anti-SARS 
RBD antibody S309 (Pinto et al., 2020) recognized half of the set of sarbecovirus RBDs, and 
C144, a more potent SARS-CoV-2 class 2 neutralizing antibody (Robbiani et al., 2020), bound 
to the SARS-CoV-2 RBD but not to RBDs from the other 11 sarbecovirus strains (Figure 1C).  
 
To further define the C022 and C118 antibody epitopes, we evaluated binding of C118 and 
C022 to a panel of RBDs with mutations chosen from circulating variants that conferred 
resistance to one or more classes of anti-RBD antibodies (Li et al., 2020; Starr et al., 2021b; 
Weisblum et al., 2020). We also assessed binding to RBD substitutions identified in the B.1.1.7 
and B.1.351 SARS-CoV-2 variants of concern (Rambaut et al., 2020; Tegally et al., 2020), and 
to mutations in the MA10 mouse-adapted SARS-CoV-2 virus (Leist et al., 2020). Relative to 
wild-type RBD, C118, C022, CR3022 and S309 demonstrated a similar binding profile with 
respect to the RBD substitutions tested and exhibited a broader range of binding to the RBD 
mutants than did the more potent class 2 C144 antibody (Figure 1C and Figure S2A). 
Collectively, the ELISA binding data suggested that C022 and C118 recognize a highly-
conserved epitope and are therefore likely to be class 4 anti-RBD antibodies. 
 
We next measured neutralization potencies using an in vitro pseudovirus-based assay that 
quantitatively correlates with authentic virus neutralization (Schmidt et al., 2020) to evaluate 
SARS-CoV-2, SARS-CoV-2 RBD mutants, SARS-CoV-2 variants (Annavajhala et al., 2021; 
Faria et al., 2021; Rambaut et al., 2020; Tegally et al., 2020; Voloch et al., 2020; West et al., 
2021; Zhang et al., 2021), and sarbecovirus strains known to infect human ACE2-expressing 
target cells (SARS-CoV-2, SARS-CoV, WIV1, SHC104, WIV16, Pangolin GD and Pangolin GX) 
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(Figure 1D and Figure S2B-D). Against a panel of SARS-CoV-2 pseudotyped viruses harboring 
single amino acid RBD substitutions, C118 and C022 neutralized all viruses with potencies 
similar to ‘wt’ SARS-CoV-2, consistent with the results obtained in ELISA binding assays (S 
gene with D614 residue; GenBank: NC_045512) (Figure S2). For comparisons with SARS-CoV-
2 variants of concern, the S gene we used to make ‘wt’ SARS-CoV-2 pseudovirus included the 
D614G substitution in the context of the Wuhan-Hu-1 spike (Korber et al., 2020), resulting in a 
2-4–fold reduction in IC50s for C022 and C118 antibodies (Figure 1D).  
 
We found that C118 and C022 IgGs neutralized all four SARS-CoV-2 variants and all ACE2-
tropic sarbecoviruses with 50% inhibitory concentrations (IC50 values) of <1 µg/mL, with the 
exception of C118, which inhibited SARS-CoV-pseudotyped viruses less efficiently (IC50 = ~4.5 
µg/mL) (Figure 1D and Figure S2B-D). By contrast, the class 4 anti-RBD antibody CR3022 
showed weak or no neutralization against the majority of pseudoviruses tested, with the 
exception of SARS-CoV (IC50 ~1.1 µg/mL) and WIV1 (IC50 ~0.6 µg/mL). The class 3 S309 
antibody showed strong neutralization potencies (IC50s between 16 ng/mL and 120 ng/mL) 
against all viruses with the exceptions of the B.1.1.7 SARS-CoV-2 variant of concern and 
SHC014. The class 2 anti-RBD antibody C144 was highly potent against SARS-CoV-2 and the 
B.1.1.7 and B.1.429 variants (IC50s between 1 ng/mL and 2 ng/mL), but did not neutralize the 
other SARS-CoV-2 variants or sarbecoviruses. Taken together, of the IgGs evaluated, C118 
and C022 exhibited the greatest breadth of sarbecovirus neutralization (Figure 1D and Figure 
S2), consistent with their broad cross-reactive binding profile demonstrated by ELISA (Figure 
1C and Figure S2A).  
 
Crystal structures of C022-RBD and C118-RBD reveal class 4 RBD interactions and 
conservation of epitope residues 
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To understand the mechanism underlying the breadth of neutralization of C022 and C118, we 
solved structures of complexes between C118 Fab bound to SARS-CoV RBD and C022 bound 
to SARS-CoV-2 RBD to resolutions of 2.7Å and 3.2Å, respectively, chosen based on which 
complexes formed well-ordered crystals (Figure 2A,B and Table S1). 
 
The C118-RBD and C022-RBD structures showed that both Fabs recognize an epitope that is 
highly-conserved among sarbecoviruses at the base of the RBD (Figure 1B), which is exposed 
only in ‘up’ RBD conformations as first described for the class 4 RBD-binding antibodies 
CR3022 (Huo et al., 2020; Yuan et al., 2020a; Yuan et al., 2020b) and EY6A (Zhou et al., 
2020a). C022 and C118 use four of six complementarity-determining region (CDR) loops to 
interact with an epitope that extends towards the RBD ridge near the ACE2 binding site, and in 
the case of C022, includes an overlapping interacting residue (K417RBD) (Figure 2C,D). In both 
structures, CDRH3 loops, CDRL2 loops, and portions of FWRL3 mediate the majority of RBD 
contacts and establish extensive polar and van der Waals interactions with RBD residues 
(Figure 2C,D), accounting for 71% of epitope buried surface area (BSA) on the RBD for the 
C022-RBD and C118-RBD structures, respectively (Table S2). No contacts were made in either 
complex with the N343RBD N-glycan (SARS-CoV-2 S numbering). SARS-CoV contains an 
additional potential N-linked glycosylation site at N357RBD (SARS-CoV S numbering), which if 
glycosylated, would not be contacted by C118, a favorable feature for cross-reactive recognition 
given that this potential N-linked glycosylation site is conserved in all S protein sequences 
except for SARS-CoV-2 (Figure 2A).  
 
Overlaying the RBDs of our Fab-RBD structures with the RBD of the ACE2-RBD structure (PDB 
6M0J) showed that the binding poses of both C118 and C022 placed the VL domain of each Fab 
in a position that would clash with concurrent ACE2 binding, in contrast to the CR3022 and 
EY6A binding poses (Figure 2E). This binding orientation would sterically prevent RBD-ACE2 
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interactions, as has been suggested for other class 4 anti-RBD antibodies (Liu et al., 2020a; 
Piccoli et al., 2020b). To verify direct competition with ACE2, we conducted a competition 
experiment using surface plasmon resonance (SPR). SARS-CoV-2 RBD was coupled to a 
biosensor chip, an RBD-binding IgG was injected, and then soluble ACE2 was injected over the 
RBD-IgG complex. C118, C022, and C144 IgGs all inhibited binding of ACE2, which did not 
bind to the IgG-RBD complex. In contrast, ACE2 bound the CR3022-RBD complex (Figure S3). 
These results are consistent with competition for C118, C022, and C144 for ACE2 binding to 
RBD, but no competition for CR3022, suggesting a primary neutralization mechanism for C022 
and C118 that prevents spike attachment to host cell ACE2 receptors. 
 
Features of C118 and C022 recognition of the class 4 epitope 
Class 4 RBD-binding antibodies contact a common epitope at the base of the RBD that is 
distant from the ACE2-binding site (Figure 3A). The epitopes of three class 4 antibodies, C118, 
C022, and COVA1-16, also includes a patch reaching towards the ridge on the left side of the 
RBD as depicted in Figure 3A.  
 
To compare the C118 and C022 epitopes with epitopes of other class 4 anti-RBD antibodies, we 
analyzed RBD residues contacted by C118, C022, COVA1-16, and CR3022 on aligned 
sequences of sarbecovirus RBDs (Figure 3B). Sequence conservation among sarbecoviruses at 
the C022 and C118 epitopes involves a majority of residues that are strictly-conserved or 
conservatively-substituted between SARS-CoV-2 and other RBDs (Figure 3B), likely explaining 
the broad cross-reactivity observed for these antibodies (Figure 1C). Comparison of the C118 
and C022 epitopes showed a majority of recognized RBD residues are shared between the two 
antibodies (70% of C118 epitope also contacted by C022) (Figure 3B). CR3022 contacted a 
similar number of residues as C118 and C022, including the conserved patch at the RBD base 
(Figure 3B,C); however, a region from 404-417RBD that comprises an unstructured loop and the 
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a4 helix above an internal RBD b-sheet contained only a single CR3022 contact residue 
(R408RBD) and was not contacted by antibodies EY6A, S2A4 and S304; whereas C118, C022, 
and COVA1-16 showed contacts with this region (Figure 3B,D). 
 
The a4 helix is proximal to the ACE2 receptor-binding motif and has less sequence 
conservation across the 12 sarbecoviruses (Figure 3B). To accommodate binding in this region, 
C118 uses insertions in its FWRL3 (54B-56LC) to form a b-strand adjacent to the a4 helix, 
establishing both side chain and backbone interactions (Figure 3E – left panel). C022 showed 
similar binding in this region but used non-contiguous CDRH1, CDRH3, and CDRL2 loops 
(Figure 3E – right panel). C022 contacts were located more to the C-terminal end of the a4 helix 
than the C118 contacts and encompassed the disordered RBD loop that includes the ACE2-
interacting residue K417RBD (K404RBD in SARS-CoV) (Lan et al., 2020) (Figure 3E – right panel). 
Additioonally, C022 buried more surface area on RBD in this region than C118 (323Å2 vs 
150Å2). Four of eight and five of nine RBD contacts for C118 and C022, respectively, were fully 
conserved among sarbecoviruses (Figure 3B), suggesting that interactions in this region may be 
possible with other sarbecoviruses. In particular, the conserved residue R408RBD (R395RBD in 
SARS-CoV) was contacted by both antibodies and alone was responsible for 94Å2 and 95Å2 of 
BSA buried on the RBDs for C118 and C022, respectively. Despite both C118 and C022 
engaging the a4 helix and residue R408RBD, mutations at this position known to affect class 1 
and class 4 anti-RBD antibodies (Greaney et al., 2021) had no effect on these antibodies 
(Figure S2A). Overall, engagement of the a4 helix region provided 16% (C118) and 36% (C022) 
of the BSA buried on RBD, and extended their epitopes past the cryptic epitope to bind adjacent 
to or overlapping with the ACE2 binding site. 
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Shared features of the C022 and COVA1-16 class 4 anti-RBD antibodies 
The C022 epitope on RBD closely resembles the epitope of COVA1-16 (Figure 3A,B), a class 4 
antibody isolated from a SARS-CoV-2 convalescent donor derived from VH1-46/VK1-33 V-gene 
segments (Brouwer et al., 2020) (Figure S4). Yet, COVA1-16 weakly neutralized (>1µg/mL) 
SARS-CoV and SARS-CoV-2 variants (Liu et al., 2021), in contrast with C022 neutralization 
(Figure 1D). After superimposing the RBDs from crystal structures of SARS-CoV-2 RBD 
complexed with COVA1-16 (PDB 7JMW) and C022 (this study), the VH-VL domains of the bound 
Fabs were related by an root mean square deviation (RMSD) of 1.3Å (235 Ca atoms), with the 
majority of conformational differences occurring in the CDRH1 and CDRH2 loops (Figure S5A). 
Despite being derived from different V gene segments (which would affect their VH gene 
segment-encoded CDRH1 and CDRH2 loops), C022 and COVA1-16 recognized similar 
epitopes, contacting a common set of 23 RBD residues, which included COVA1-16 interactions 
in common with C022 interactions with the RBD a4 helix (Figure 3B).  
 
While C022 and COVA1-16 share a generally similar mode of binding, there are differences in 
interactions of residues encoded within their different VH gene segments (i.e., their CDRH1 and 
CDRH2 loops) (Figure S5B). For example, the C022 contact with T430RBD was part of an 
extensive clasp made by an interaction between the C022 CDRH1 residue R33HC with 
backbone carbonyls of D427RBD, D428RBD, and F429RBD and with the sidechain of T430RBD 
(Figure S5C). Two of the same RBD residues (D427RBD and F429RBD) interacted with an 
arginine from COVA1-16, but this arginine (R100BHC) is located at the base of the CDRH3 loop 
rather than within CDRH1, as is the case with C022 R33HC. The larger separation distance from 
the RBD of COVA1-16 R100BHC allowed it to form a sidechain-backbone H-bond with D427RBD 
similar to a sidechain–backbone H-bond involving C022 R33HC and D428RBD, but precluded 
interactions with D428RBD and T430RBD (Figure S5D). In addition, the COVA1-16 CDRH1 was 
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shorter than the C022 CDRH1 (7 versus 9 residues) (Figure S4A), and was shifted away from 
the RBD relative to the C022 CDRH1. These differences, in addition to fewer LC interactions by 
COVA1-16, resulted in less total BSA for COVA1-16 relative to C022 (1607 Å2 vs 1875 Å2, 
respectively) despite similar contributions from CDRH3 loops (Table S2). 
 
Interactions with RBD main chain atoms facilitate recognition of diverse RBDs  
The paratopes of both C118 and C022 were dominated by their long CDRH3 loops (20 and 21 
residues, respectively) (Figure 4A,B and Figure S4), which make up ~half of the buried surface 
areas (BSAs) of each paratope (461 Å2 of 1020 Å2 for C118 and 537 Å2 of 969 Å2 for C022) 
(Table S2). The C118 and C022 CDRH3s comprise two anti-parallel b-strands that extend a 
largely internal RBD b-sheet (b-strands b1-b4 and b7) through main chain H-bonds between the 
RBD b2 strand (377-379RBD) and the first CDRH3 b-strand (CDRH3 residues 97-99 (C118) or 
100-100B (C022)) (Figure 4A,B). A similar feature is also seen in the structure of the COVA1-
16–RBD complex (Liu et al., 2020a), which shares a nearly identical CDRH3 sequence with 
C022 (Figure S5E). 
 
C118 and C022 form extensive backbone interactions with RBD, with 10 and 9 H-bonds formed 
with the backbone of RBD, respectively. Extensive backbone interactions in the C118 and C022 
epitopes could contribute to their breadth of binding and neutralization across sarbecoviruses, 
as backbone interactions would facilitate binding despite side chain substitutions, which are rare 
across the RBD sequences listed (Figure 3B), but could occur in other CoV RBDs. For example, 
the backbone H-bonds between the CDRH3s of C118 and C022 with the RBD b2 strand allow 
for binding despite substitution at position K378RBD (K365RBD in SARS-CoV) (Figure S2A and 
Figure 4C). By contrast, the class 4 antibody CR3022 uses side chain interactions (potential 
electrostatic interactions between D54HC and E56HC and K378RBD); thus CR3022 is sensitive to 
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mutation at K378NRBD (Figure S2A). This is consistent with CR3022 not binding to Rf1-CoV 
RBD (Figure 1C), which contains an asparagine at the equivalent position to SARS-CoV-2 
K378RBD (Figure 3B), whereas C118 and C022 binding to Rf1-CoV RBD was not affected. 
Overall, mainchain H-bond interactions likely reduce sensitivity to RBD sidechain substitutions, 
making antibodies such as C118 and C022 more tolerant to differences between 
sarbecoviruses strains or variants.  
 
C118-S cryo-EM structure shows increased S trimer opening 
On an S trimer, the class 4 cryptic epitope is at the base of the RBD, where it faces towards the 
center of the trimer (Barnes et al., 2020a; Huo et al., 2020; Yuan et al., 2020b). The epitope is 
buried in the closed, prefusion S conformation and interacts with portions of the spike S2 
subunit and neighboring ‘down’ RBDs. Compared to class 2 or class 3 anti-RBD antibodies that 
recognize their epitopes in ‘up’ or ‘down’ RBD conformations (Barnes et al., 2020a), the class 4 
epitope is less accessible and requires two ‘up’ RBDs for antibody binding (Piccoli et al., 
2020b). Additionally, class 4 antibody binding may also require RBD rotation to prevent steric 
clashes with neighboring ‘up’ RBDs, as observed for the complexes of S trimer with EY6A, 
S2A4, and S304 (Piccoli et al., 2020b; Zhou et al., 2020a).  
 
Given the similar binding poses of C118 and C022 antibodies, which bind with a more acute 
angle with respect to the RBD than EY6A or CR3022 (Figure 2E), and the increased breadth 
and potency of C118 and C022 relative to other class 4 anti-RBD antibodies (Figure 1D), we 
sought to understand the requirements for epitope recognition on a S trimer. Thus, we solved a 
single-particle cryo-EM structure of C118 Fabs bound to SARS-CoV-2 S 6P trimers (Hsieh et 
al., 2020), finding two distinct states defined by RBDs adopting various rotational conformations 
(Figure 5A,B and Figure S6), as well as C118 Fab bound to dissociated S1 subunit protomers 
(Figure S6B). For the state 1 C118-S trimer complex structure solved to 3.4Å, we subsequently 
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used symmetry expansion and local refinement to generate a 3.7Å map of the C118 VHVL – 
RBD interface (Figure S6B-E).  
 
The C118 pose with respect to the RBD observed in the C118 – SARS-CoV-2 S structure was 
similar to the C118 – SARS-CoV RBD crystal structure (Figure S6F), demonstrating consistent 
recognition of the antibody epitope on both SARS-CoV-2 and SARS-CoV RBDs. Furthermore, 
the C118 binding pose was oriented higher on the RBD relative to other class 4 anti-RBD 
antibodies (Figure 5C), and was consistent with SPR competition data that suggested C118 
would sterically hinder ACE2 binding to the same protomer (Figure S3). 
 
Despite differences in binding poses relative to other class 4 antibodies (Figure 5C), C118 
binding also resulted in RBD conformations displaced further from the trimer center relative to 
S2E12 (a class 1 anti-RBD neutralizing antibody) (Tortorici, 2020) and ACE2 (Yan et al., 2020) 
(Figure 5D). On average, class 4 anti-RBD antibody binding resulted in an ~15-20Å 
displacement of the RBD relative to ACE2-bound conformations, which likely results in 
destabilization of the spike trimer. Indeed, S1 shedding induced by class 4 antibodies has been 
described as a possible neutralization mechanism (Huo et al., 2020; Piccoli et al., 2020b; Wec 
et al., 2020). The presence of C118-S1 protomer classes in our cryo-EM data suggested that 
C118 also induces shedding (Figure S6), but the role S1 shedding and premature S-triggering 
plays in C118-mediated neutralization requires further investigation. 
 
C118 and C022 neutralization of sarbecoviruses demonstrate differential effects of 
avidity enhancement 
Neutralization of SARS-CoV-2 and SARS-CoV by COVA1-16 was found to be mediated by 
avidity effects based on potent neutralization by the bivalent COVA1-16 IgG, but not the 
monovalent Fab (Liu et al., 2020a). To evaluate whether intra-spike crosslinking, one source of 
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avidity enhancement for bivalent antibodies, was possible for C118 or C022 IgGs, we examined 
the C118-S trimer structure to ask whether the positioning of two Fabs on adjacent RBDs would 
be compatible with binding by a single IgG. As previously described for other anti-RBD IgGs, we 
compared the distance between residues near the C-termini of adjacent Fab CH1 domains to 
analogous distances in crystal structures of intact IgGs, setting a cut-off of ≤65Å as potentially 
allowing a single IgG to include both Fabs (Barnes et al., 2020a). The measured distance for the 
C-termini of adjacent Fab CH1 domains in the symmetric State 1 C118-S trimer structure was 
41Å (Figure 5E), suggesting that intra-spike crosslinking would be possible for C118 IgGs 
bound to spike trimers. The asymmetric State 2 C118-S structure included distances of 50Å, 
89Å, and 92Å (Figure 5E), also allowing intra-spike crosslinking between one combination of 
two bound RBDs, as well as the potential for inter-spike crosslinking between adjacent spikes 
on the virion surface. In comparison, no other class 4 anti-RBD Fab-S trimer structures showed 
measured distances that would be compatible with intra-spike crosslinking (Figure 5E), thus any 
potential avidity effects for those IgGs could only occur via inter-spike crosslinking. 
 
To further evaluate whether avidity could also facilitate cross-reactive neutralization by the C118 
and C022 antibodies, we compared neutralization of SARS-CoV-2, SARS-CoV, WIV1, and 
SHC014 by the bivalent C118 and C022 IgGs and by two monovalent forms of each antibody: a 
50 kDa Fab and an IgG size-matched bispecific IgG containing only one relevant Fab. The 
bispecific IgGs included one C118 or C022 RBD-binding Fab and a second non-RBD-binding 
Fab derived from the HIV-1 antibody 3BNC117 (Scheid et al., 2011). To interpret neutralization 
results, we calculated molar neutralization ratios (MNRs) defined as: [IC50 Fab or bispecific IgG 
(nM)/IC50 IgG (nM)] (Klein and Bjorkman, 2010). In the absence of avidity effects resulting from 
either crosslinking within a spike trimer (intra-spike crosslinking) or cross-linking between 
adjacent spike trimers (inter-spike crosslinking), an MNR would be 2.0, which accounts for twice 
as many relevant Fabs in a bivalent IgG compared to its monovalent forms.  
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Using pseudotyped SARS-CoV-2, SARS-CoV, WIV1, and SHC014, we derived neutralization 
potencies of the bivalent IgG, monovalent bispecific IgG, and Fab forms of C118 and C022 and 
then calculated MNRs for the bivalent IgG to bispecific IgG comparison (bispecific MNR) and for 
the bivalent IgG to Fab comparison (Fab MNR) (Figure 5F). Comparisons between the Fab and 
bispecific IgG forms of monovalent antibody allowed evaluation of potential steric affects that 
could increase neutralization potencies for larger IgGs compared to smaller Fabs. With the 
exception of the low MNRs derived from the IgG comparison with the bispecific and Fab forms 
of C118 against SARS-CoV-2 (MNRs of 5 and 3, respectively), we found mostly high MNRs 
ranging from the lowest values of >11 and 28 for the MNRs for C118 against SARS-CoV (where 
11 is a minimal estimate since the C118 bispecific was non-neutralizing) to the highest values of 
708 and 1444 for the C022 bispecific and Fab MNRs against SHC014. Four of the bispecific to 
Fab MNR comparisons showed a two-fold or higher Fab MNR than the comparable bispecific 
MNR, suggesting that at least some of the increased potencies of the bivalent IgGs compared 
with their counterpart Fabs resulted from steric effects. However, six of the eight monovalent to 
bivalent comparisons exhibited MNRs well over 70, suggestive of strong avidity effects. By 
contrast, mean MNRs derived for broadly neutralizing anti-HIV-1 Env antibodies are ≤10 (Wang 
et al., 2017), consistent with the low spike density on HIV-1 virions that largely prevents inter-
spike crosslinking, and the architecture of the HIV-1 Env trimer, which prohibits intra-spike 
crosslinking for all known HIV-1 broadly neutralizing antibodies (Klein and Bjorkman, 2010). 
Taken together with the analysis of the C118-S trimer structure, the observed avidity effects for 
C118 IgGs binding to WIV1 and SHC014 and for the related C022 IgGs binding to the four 
viruses tested could arise from intra-spike as well as inter-spike crosslinking.  
 
The question as to why C118 exhibits little or no avidity effects for neutralization of SARS-CoV-2 
and SARS-CoV is difficult to address since the same IgG showed strong avidity effects against 
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WIV1 and SHC014, and C022, which binds similarly to C118, showed avidity effects in 
neutralization of all four pseudoviruses. These results could derive from different binding 
characteristics for C118 to the SARS-CoV-2 and SARS-CoV RBDs compared with C118 and 
C022 interactions with the other sarbecoviruses evaluated. Indeed, simulations of avidity effects 
demonstrated that some combinations of IgG concentration and antigen-binding affinity and 
kinetic constants showed no advantages of bivalent versus monovalent binding (Klein, 2009; 
Klein and Bjorkman, 2010). Thus the effects of avidity are a complicated function of 
concentration and binding constants that preclude predictions in the absence of experimental 
data.   
 
Discussion 
Concerns about coronaviruses having spillover potential as well as the increasing prevalence of 
SARS-CoV-2 variants necessitates identification of cross-reactive antibodies. Antibodies elicited 
against infectious viruses for which there are multiple circulating variants, either within an 
individual or the population, often show a trade-off between potency and breadth (Corti et al., 
2010; Desrosiers et al., 2016). In the case of antibody responses against SARS-CoV-2, the 
cause of the current global pandemic, many strongly neutralizing antibodies have been isolated 
that block ACE2 receptor interactions (Barnes et al., 2020a; Dejnirattisai et al., 2021; Lee et al., 
2021; Liu et al., 2020b; Piccoli et al., 2020a). However, the ACE2-binding region of the RBD 
also tends to accumulate amino acid changes, as evidenced by substitutions identified in the 
current SARS-CoV-2 variants of concern (Annavajhala et al., 2021; Faria et al., 2021; Rambaut 
et al., 2020; Tegally et al., 2020; Voloch et al., 2020; West et al., 2021; Zhang et al., 2021), thus 
reducing the potential efficacies of vaccines and monoclonal antibody therapies. Recent studies 
suggest that antibodies against the S2 subunit offer the potential of greater cross-reactivity 
across coronaviruses, but these antibodies generally lack strong neutralization potency (Sauer 
et al., 2021; Shah et al., 2021; Wang et al., 2021).  
.CC-BY-NC 4.0 International licenseavailable under a
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprint (whichthis version posted April 26, 2021. ; https://doi.org/10.1101/2021.04.23.441195doi: bioRxiv preprint 
 18 
 
The class 4 RBD-binding epitope, which is more conserved than the class 1 and class 2 RBD 
epitopes, represents a plausible target for the elicitation of antibodies with broad cross-reactive 
recognition across sarbecoviruses. Indeed, some recently described class 4 antibodies (e.g., 
CR3022, H014, COVA1-16, EY6A, ADI-56046) neutralize two or more sarbecovirus strains, 
and/or can bind RBDs from multiple sarbecoviruses (Liu et al., 2020a). However, while many 
class 4 antibodies show some cross-reactivity, they generally exhibit decreased potencies 
against heterologous sarbecovirus strains. For example, the SARS-CoV–derived CR3022 
antibody does not potently neutralize SARS-COV-2 (Huo et al., 2020), and the SARS-CoV-2 – 
derived COVA1-16 antibody does not potently neutralize SARS-CoV or SARS-CoV-2 variants of 
concern (Liu et al., 2020a; Liu et al., 2021).  
 
Here we characterized two antibodies, C118 and C022, derived from different COVID-19 
convalescent donors (Robbiani et al., 2020), which show breadth of and potent neutralization 
against sarbecoviruses of all three clades. The structural similarity of RBD binding poses 
between C022 and COVA1-16 (Liu et al., 2020a), which was derived from yet a third COVID-19 
convalescent donor (Brouwer et al., 2020), suggests that these sorts of cross-reactive 
antibodies are commonly elicited by natural infection and that their epitope represents an 
attractive target for immunogen design. Of particular importance for the current pandemic, 
circulating variants of concern or variants of interest did not confer resistance to the C118 and 
C022 antibodies. In addition, C118 and C022 antibodies were not affected by naturally-
occurring RBD mutations that undermine the activity of several antibodies approved for 
therapeutic use (Hoffmann et al., 2021; Starr et al., 2021b).  
 
Analysis of our C118-RBD and C022-RBD complex structures revealed key details of cross-
reactive recognition and broad sarbecovirus neutralization. First, C118 and C022 utilize long 
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CDRH3s to facilitate interactions with the cryptic RBD epitope at the base of the RBD. In 
contrast to less potent class 4 antibodies such as CR3022 (Huo et al., 2020; Yuan et al., 2020a; 
Yuan et al., 2020b) and EY6A (Zhou et al., 2020a) that also contact this region, the longer 
CDRH3 provides the opportunity to target a highly-conserved patch of residues across 
sarbecoviruses with an orientation that extends the epitope upwards to the ACE2 binding site, a 
structural feature shared with COVA1-16 (Liu et al., 2020a). Second, the aforementioned 
binding poses of C118, C022, and COVA1-16, as well as overlap of the C022 epitope with the 
edge of the ACE2 binding site, suggested competition with ACE2 as part of their neutralization 
mechanisms. Indeed, competition experiments reported here for C118 and C022 and by others 
for COVA1-16 (Liu et al., 2020a) demonstrated competition with ACE2 for SARS-CoV-2 RBD 
binding. Third, C118 and C022 formed many interactions with backbone atoms of RBD 
residues, adding a second level of buffering against viral escape since amino acid substitutions 
at these positions are less likely to abrogate antibody binding. Finally, the demonstration that 
C118 and C022 bivalency increased potency of neutralization against some of the viruses 
evaluated showed the potential for these antibodies to utilize avidity effects for neutralization of 
sarbecoviruses. Given the requirement for two ‘up’ RBDs on a S trimer for class 4 antibody 
binding, bivalent binding within a single S trimer would be possible. Thus we suggest that intra-
spike crosslinking would be an advantage for neutralization of sarbecoviruses, where avidity 
effects likely play a role. 
 
In conclusion, class 4 antibodies that access the cryptic RBD epitope and compete with ACE2 
binding are important for understanding cross-reactivity of human SARS-CoV-2 antibody 
responses elicited by natural sarbecovirus infection. We suggest that potent class 4 anti-RBD 
antibodies could be used therapeutically to avoid resistance to SARS-CoV-2 variants of 
concern, perhaps after in vitro selection to further improve their potencies. Structural 
characterization of these antibodies could also be used to inform future immunogen design 
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Figure 1. C118 and C022 show diverse binding and neutralization of sarbecoviruses  
(A) Sarbecovirus (Lineage B) phylogenetic tree classified based on RBD sequence 
conservation. 
(B) Left: Cartoon rendering of SARS-CoV-2 S trimer (PDB 6VYB) showing location of ‘up’ RBD 
(surface, orange and purple). Right: Amino acid sequence conservation of 12 RBDs calculated 
as described (Landau et al., 2005) plotted on a surface representation of a SARS-CoV-2 RBD 
structure (PDB 7BZ5). Primary RBD epitopes for the indicated representatives from defined 
classes of RBD-binding antibodies (class 1-4) (Barnes et al., 2020a) are indicated as yellow 
dotted lines (PDB 7K90, 6W41, 7JX3,7K8M). C022 epitope indicated as blue dotted line. 
(C) Comparison of binding of the indicated monoclonal IgGs to a panel of sarbecovirus RBDs 
from ELISA data shown as area under the curve (AUC) values. Data presented are mean AUC 
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values from two independent experiments. IOMA IgG is an anti-HIV-1 antibody serving as a 
negative control (Gristick et al., 2016). 
(D) Neutralization IC50 values for the indicated IgGs against SARS-CoV-2 (D614G version of the 
original variant (GenBank: NC_045512)), SARS-CoV-2 variants of concern, and other ACE2-
tropic sarbecovirus pseudoviruses. Geomean = geometric mean IC50 in which IC50 values 
>50000ng/mL were entered as 50000 ng/mL for the calculation. SD = standard deviation. IC50 
values are means of 2-7 independent experiments.  
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Figure 2.  Crystal structures of C022 and C118 Fabs bound to RBDs reveal class 4-like 
RBD binding.  
(A,B) Cartoon renderings of crystal structures of (A) C0118 Fab complexed with SARS-CoV 
RBD, and (B) C022 Fab complexed with SARS-CoV-2 RBD. Dashed circle shows location of 
SARS-CoV N357RBD residue, with the inset showing the N357RBD asparagine and glycan 
modeled based on the SARS-CoV spike-S230 structure (PDB 6NB6). 
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(C,D) CDR loops and RBD epitope residues of (C) C118 Fab and (D) C022 Fab overlaid on 
RBDs represented as gray surfaces with stick representations of epitope residues. Framework 
region residues, which account for some of the contacts for both antibodies, are not shown in 
right panels. 
(E) Comparison of Fab poses for binding to an RBD-ACE2 complex. C118 Fab (blue), C022 
Fab (red), CR3022 Fab (PDB 6W41; orange), and EY6A Fab (PDB 6CZC pink) modeled onto 
an ACE2-RBD structure (PDB 6M0J; RBD shown as a gray surface and ACE2 shown as a 
green cartoon).  
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Figure 3. The C118 and C022 epitopes include a conserved RBD helix. 
(A) Epitopes for ACE2 and monoclonal antibodies calculated from analyses of structures of 
RBD or S trimer complexes (human antibodies isolated from COVID-19 patients are C118, 
C022, COVA1-16, EY6A, and S2A4). RBDs shown are derived from SARS-CoV-2 except for 
the C118 panel, which is SARS-CoV RBD.  
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(B) Alignment of sequences for sarbecovirus RBDs (residue numbering for SARS-CoV-2 RBD). 
Secondary structure for SARS-CoV-2 RBD shown above alignment. Dots designate binding or 
neutralization for C118 (blue), C022 (red), or CR3022 (orange) for each strain. Diamonds 
designate RBD epitope residues for C118 binding to SARS-CoV (blue) and C022 (red) or 
CR3022 (orange) binding to SARS-CoV-2. Left boxes show binding by ELISA or neutralization 
of pseudovirus for each antibody for each strain; data for COVA1-16 from (Liu et al., 2020a). 
Circles show binding or neutralization, blank spaces designate not tested, and dashes 
designate no binding or neutralization. Shadings in the sequence alignment indicate conserved 
portions of epitope (green). Colored boxes show differing portion of epitope covering the a4 
helix and following loop (pink. 
(C) Cartoon representation of SARS-CoV-2 RBD (gray) showing overlapping antibody-
interacting residues (green) as sticks in epitopes for C118, C022, COVA1-16, and CR3022 
(corresponding to green shading in panel B).  
(D) Cartoon representation of SARS-CoV-2 RBD (gray) showing a4 helix and following (sticks, 
pink) that differ in their contacts with C118, C022, COVA1-16, and CR3022 (pink shading in 
panel B).  
(E) Cartoon representation of RBDs showing a4 region of RBD and C118 (left) or C022 (right) 
interacting loops with interacting Fab residues in light blue (C118) and light pink (C022). 
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Figure 4: C118 and C022 Fabs primarily use their CDRH3s for contacts with RBD 
alternative binding contacts for K378RBD.   
(A) Close-up cartoon showing b-hairpin formed by C118 CDRH3 (blue sticks) and b-sheet 
formation with SARS-CoV RBD (grey cartoon with sticks). H-bonds shown as black dashed 
lines.  
(B) Close-up cartoon showing b-hairpin formed by C022 CDRH3 (red sticks) and b-sheet 
formation with SARS-CoV-2 RBD (grey cartoon with sticks). H-bonds shown as black dashed 
lines.  
(C) Cartoon and stick representation of C118-RBD (left), C022-RBD (middle) and CR3022-RBD 
(right) showing distinct interactions with residue K365SARS/K378SARS2 (cyan).  
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Figure 5. Cryo-EM structure of C118-S complex shows binding to cryptic epitope and the 
potential for intra-spike crosslinking. 
(A) 3.4Å cryo-EM density for the C118 – S trimer complex (State 1). Side view (left panel) 
illustrates orientation with respect to the viral membrane (dashed line). Top view (right panel) 
shows symmetric binding at the trimer apex with C118 HC (blue) oriented in the interior.  
(B) 4.4Å cryo-EM density for the C118 – S trimer complex (State 2). Top view illustrates 
asymmetry of complex due to RBD rotation in one protomer.  
(C) Composite model of an open SARS-CoV-2 trimer bound by class 4 Fabs: C118 (this paper, 
blue), EY6A (PDB 6ZDH, pink), S2A4 (PDB 7JVC, brown), the class 4 anti-SARS antibody 
S304 (PDB 7JW0, green), and H014 (PDB 7CAK, yellow).  
(D) Comparison of S trimer openness by measurements of Ca distances for D428RBD between 
adjacent ‘up’ RBDs in S trimers complexed with: the class 1 antibody S2E12 (PDB 7K43, gray), 
soluble ACE2 (PDB 7KMS, green) and the class 4 antibodies C118 (this study, blue) and EY6A 
(PDB 6ZDH, pink).  
(E) Prediction of potential intra-spike avidity effects by measurement of Ca distances between 
the C-termini of adjacent CH1 domains for the mAb-S trimer complexes described in panel C. 
Measurements were used to evaluate the potential for intra-spike crosslinking by an IgG binding 
to a single spike trimer as described (Barnes et al., 2020a). For the H014-S complex, the CH1-
CL domains were rigid body fit into the cryo-EM density (EMD-30333) prior to measurements.  
(F) IC50 values and molar neutralization ratios (MNRs) defined as: [IC50 Fab or bispecific IgG 
(nM)/IC50 IgG (nM)] (Klein and Bjorkman, 2010) for C118 and C022. IC50 values shown for the 
IgGs are from Figure 1D. IC50 values for all assays against SARS-CoV-2 and SARS-CoV are 
means of 2-7 independent experiments. Two MNRs are presented in the MNRs (bispecific/Fab) 
column: the MNR calculated using a bispecific IgG versus the bivalent IgG (left) and the MNR 
calculated using a Fab versus the bivalent IgG (right). Neutralization results with MNRs ≤5 are 
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indicated as not demonstrating avidity effects (-), >10 are indicated as demonstrating minimal 
avidity (+), results with one MNR> 50 are indicated as moderate avidity (++), and MNRs 
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All requests for further information or reagents should be directed to the Lead Contact, Pamela 
Bjorkman (bjorkman@caltech.edu).  
Materials Availability 
All expression plasmids generated in this study for human CoV proteins, Fabs and IgGs are 
available upon request. 
Data and Code Availability 
Atomic models of C118 Fab complexed with SARS-CoV RBD and C022 Fab complexed with 
SARS-CoV-2 RBD have been deposited in the Protein Data Bank (PDB) (http://www. rcsb.org/) 
under accession codes XXXX and YYYY, respectively. The atomic model and cryo-EM map 
generated for the C118 Fab–SARS-CoV-2 S complex have been deposited at the PDB 
(http://www.rcsb.org/) and the Electron Microscopy Databank (EMDB) 
(http://www.emdataresource.org/) under accession codes AAAA and EMD-BBBBB, respectively. 
 
EXPERIMENTAL MODEL DETAILS 
 
Cell lines 
Cells for pseudovirus production (HEK293T) were cultured at 37°C and 5% CO2 in Dulbecco’s 
modified Eagle’s medium (DMEM, Gibco) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS, Sigma-Aldrich) and 5 µg/ml Gentamicin (Sigma-Aldrich).  
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Target cells for pseudovirus neutralization experiments (HEK293TACE2) were generated as 
described (Robbiani et al., 2020) and cultured at 37°C and 5% CO2 in Dulbecco’s modified 
Eagle’s medium (DMEM, Gibco) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS, Sigma-Aldrich), 5 µg/ml gentamicin (Sigma-Aldrich), and 5µg/mL Blasticidin (Gibco).  
 
Expi293F cells (Gibco) for protein expression were maintained at 37°C and 8% CO2 in Expi293 
expression medium (Gibco), transfected using an Expi293 Expression System Kit (Gibco) and 




E. coli DH5 Alpha (Zymo Research) used for propagation of expression plasmids were cultured 
with shaking at 250 rpm at 37˚C in LB broth (Sigma-Aldrich). 
 
Viruses 
To generate pseudotyped viral stocks, HEK293T cells were transfected with pNL4-3∆Env-
nanoluc and pSARS-CoV2-Strunc (Robbiani et al., 2020) using polyethylenimine, leading to 
production of HIV-1-based pseudovirions carrying the SARS-CoV-2 S protein at the surface. 
Eight hours after transfection, cells were washed twice with phosphate buffered saline (PBS) 
and fresh media was added. Supernatants containing pseudovirus were harvested 48 hours 
post transfection, filtered and stored at -80°C. Infectivity of pseudoviruses was determined by 
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Phylogenetic trees 
Sequence alignments of RBDs were made with Clustal Omega (Sievers et al., 2011). 
Phylogenetic trees were calculated from amino acid alignments using PhyML 3.0 (Guindon et 
al., 2010) and visualized with PRESTO (http://www.atgc-montpellier.fr/presto). 
 
Protein Expression 
Fabs and IgGs were expressed and purified as previously described (Scharf et al., 2015; 
Schoofs et al., 2019) and stored at 4 °C. Bispecific IgGs (C118 or C022 plus 3BNC117, a non-
coronavirus binding HIV-1 antibody (Scheid et al., 2011)) were produced by co-transfection of 
two heavy chain and two light chain genes that included knobs-into-holes mutations in IgG Fc 
and a domain cross-over in the 3BNC117 Fab to prevent incorrect light chain pairing (Schaefer 
et al., 2011). Antibody CDR lengths were determined using the IMGT definitions (Lefranc et al., 
2015; Lefranc et al., 2009).  
 
The following C-terminally 6xHis-tagged RBD proteins were transfected and expressed as 
described previously (Cohen et al., 2021): SARS-CoV-2 RBD (residues 328-533), SARS-CoV-2 
RBD mutants (residues 319-541), SARS RBD (residues 318-510), SHC014 RBD (residues 307-
524), WIV-1 RBD (residues 307-528), RaTG13 RBD (residues 319-541), Rs4081 RBD 
(residues 310-515), Yun11 RBD (residues 310-515), Rf1 RBD (residues 310-515), RmYN02 
RBD (298-503), BM-4831 RBD (residues 310-530), BtKY72 RBD (residues 309-530). A trimeric 
SARS-CoV-2 ectodomain (residues 16-1206 of the early SARS-CoV-2 GenBank MN985325.1 
sequence isolate with 6P (Hsieh et al., 2020) stabilizing mutations, a mutated furin cleavage site 
between S1 and S2, a C-terminal TEV site, foldon trimerization motif, octa-His tag, and AviTag) 
was expressed as described (Barnes et al., 2020a; Barnes et al., 2020b). A gene encoding a 
6xHis-tagged soluble human ACE2 construct (residues 1-615) was purchased from Addgene 
(Catalog # 149268) and expressed and purified as described (Chan et al., 2020).  
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SARS-CoV-2 S trimer, RBDs, and soluble ACE2 were purified by Nickel-NTA and size-
exclusion chromatography using a Superdex 200 column (GE Life Sciences) as described 
(Barnes et al., 2020a; Cohen et al., 2021). Peak fractions were identified by SDS-PAGE, and 
those containing S trimer, monomeric RBDs, or soluble ACE2 were pooled, concentrated, and 
stored at  4 °C (RBDs) or flash frozen in nitrogen and stored at -80 °C (S trimer) until use. 
 
ELISAs 
Purified RBD at 10 µg/ml in 0.1 M NaHCO3 pH 9.8 was coated onto Nunc® MaxiSorp™ 384-
well plates (Sigma) and stored overnight at 4oC. The following day, plates were blocked with 3% 
bovine serum albumin (BSA) in TBS-T Buffer (TBS + 0.1% Tween20) for 1hr at room 
temperature. Blocking solution was removed from the plates, purified IgGs at 50 µg/mL were 
serially diluted by 4-fold with TBS-T/3% BSA and added to plates for 3 hr at room temperature. 
Plates were washed with TBS-T and then incubated with 1:15,000 dilution of secondary HRP-
conjugated goat anti-human IgG for 45 minutes at room temperature (Southern Biotech). Plates 
were washed again with TBS-T and developed using SuperSignal™ ELISA Femto Maximum 
Sensitivity Substrate (ThermoFisher) and read at 425 nm. ELISAs were done in duplicate, and 
curves were plotted and integrated to obtain the area under the curve (AUC) using Graphpad 
Prism v9.1.0.  
 
Neutralization assays 
SARS-CoV-2, SARS-CoV-2 variants of concern (Annavajhala et al., 2021; Faria et al., 2021; 
Rambaut et al., 2020; Tegally et al., 2020; Voloch et al., 2020; West et al., 2021; Zhang et al., 
2021), SARS-CoV, WIV1, and SHC014 pseudoviruses based on HIV-1 lentiviral particles were 
prepared as described (Cohen et al., 2021; Crawford et al., 2020; Robbiani et al., 2020) using 
genes encoding S protein sequences with cytoplasmic tail deletions: 21 amino acid deletions for 
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SARS-CoV-2, SARS-CoV-2 variants of concern, WIV1, and SHC014 and a 19 amino acid 
deletion for SARS-CoV. Plasmids expressing the spike protein found in the bat (Rinolophus 
Sinicus) coronavirus bCoV-WIV16 as well as the pangolin (Manis javanica) coronaviruses from 
Guandong, China (pCoV-GD) and Guanxi, China (pCoV-GX) have been described previously 
and are based on ALK02457 (Genebank), Pangolin_CoV_EPI_ISL_410721(Gisaid) and 
Pangolin_CoV_EPI_ISL_410542 (Gisaid) (Muecksch et al., 2021).  
 
Relative to the SARS-CoV-2 spike gene (Wuhan-Hu-1 Spike Glycoprotein Gene, D614G 
mutant, designated as ‘wt’ in Figure 1D), the SARS-CoV-2 variants of concern included the 
D614G mutation and the following other substitutions: B.1.351: L18F, D80A, D215G, del242-
244, R246I, K417N, E484K, N501Y, A701V; B.1.1.7: del69-70, del144, N501Y, A570D, P681H, 
T716I, S982A, D1118H; B.1.429: S13I, W152C, L452R, and B.1.526: L5F, T95I, D253G, 
E484K, A701V. For neutralization assays presented in Figure 1D, four-fold dilutions of purified 
IgGs (starting concentrations of 50 µg/mL) were incubated with a pseudotyped virus for 1 hour 
at 37˚C. Cells were washed twice with phosphate-buffered saline (PBS) and lysed with 
Luciferase Cell Culture Lysis 5x reagent (Promega) after incubation with 293TACE2 target cells 
for 48 hours at 37˚C. NanoLuc Luciferase activity in lysates was measured using the Nano-Glo 
Luciferase Assay System (Promega). Relative luminescence units (RLUs) were normalized to 
values derived from cells infected with pseudotyped virus in the absence of IgG. Half-maximal 
inhibitory concentrations (IC50 values) were determined using 4- or 5-parameter nonlinear 
regression in AntibodyDatabase (West et al., 2013). 
 
Relative to the SARS-CoV-2 spike gene (Wuhan-Hu-1; NC_045512, D614 sequence designated 
as ‘wt’ in Figure S2), a panel of plasmids expressing RBD mutant SARS-CoV-2 S proteins in the 
context of pSARS-CoV-2-SΔ19 have been described previously (Muecksch et al., 2021; Robbiani 
et al., 2020; Schmidt et al., 2020; Weisblum et al., 2020). The E484K substitution was constructed 
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in the context of a pSARS-CoV-2-SΔ19 variant with a mutation in the furin cleavage site (R683G) 
to increase infectivity (Muecksch et al., 2021). The IC50 values of this pseudotype (E484K/R683G) 
was compared to a wild-type SARS-CoV-2 S sequence carrying R683G in the subsequent 
analyses. For neutralization assays presented in Figure S2, monoclonal antibodies were four-fold 
serially diluted and incubated with SARS-CoV-2 pseudotyped HIV-1 reporter virus for 1 h at 37 °C 
(final starting concentration of 2.5 µg/ml). The antibody and pseudotyped virus mixture was added 
to HT1080ACE2.cl 14 cells (Schmidt et al., 2020). After 48 h, cells were washed with PBS and 
lysed with Luciferase Cell Culture Lysis 5× reagent (Promega). Nanoluc luciferase activity in cell 
lysates was measured using the Nano-Glo Luciferase Assay System (Promega) and the Glomax 
Navigator (Promega). Relative luminescence units were normalized to those derived from cells 
infected with SARS-CoV-2 pseudovirus in the absence of monoclonal antibodies. The 50% 
inhibitory concentration (IC50) was determined using 4-parameter nonlinear regression (least-
squares regression method without weighting; constraints: top = 1, bottom = 0) (GraphPad 
Prism). 
 
SPR-based ACE2 binding competition experiments 
Surface Plasmon Resonance (SPR) experiments were done using a Biacore T200 instrument 
(GE Healthcare).  
 
Surface Plasmon Resonance (SPR) experiments were done using a Biacore T200 instrument 
(GE Healthcare). Purified SARS CoV-2 RBD was conjugated to each of the four flow cells using 
primary amine chemistry at pH 4.5 (Biacore manual) to a CM5 chip (GE Healthcare) to a 
response level of ~700 resonance units (RUs). C118, C022, C144, and CR3022 IgG (1000nM) 
in buffer HBS-EP+ (150mM sodium chloride, 10mM HEPES, 3mM EDTA, 0.05% Tween-20, pH 
7.6) were each injected on the RBD-CM5 chip for a contact time of 600 sec at 30µL/min. A 
second injection of soluble ACE2 at 250nM was injected over the immobilized RBD-Fab at 
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30µL/min for a contact time of 300 sec and dissociation time of 30 sec in HBS-EP+ buffer. Data 
were analyzed and plotted using Prism 9 (Graphpad).  
 
X-ray crystallography 
Fab-RBD complexes were assembled by incubating an RBD with a 1.5x molar excess of Fab for 
1 hr on ice followed by size exclusion chromatography on an S200 10/300 increase column (GE 
Life Sciences). Fractions containing complex were pooled and concentrated to 8mg/mL. 
Crystallization trials using commercially-available screens (Hampton Research) were performed 
at room temperature using the sitting drop vapor diffusion method by mixing equal volumes of a 
Fab-RBD complex and reservoir using a TTP LabTech Mosquito instrument. Crystals were 
obtained for C118 Fab-SARS RBD in 0.2M sodium fluoride, 20% w/v polyethylene glycol 3,350 
and for C022 Fab-SARS-CoV-2 RBD in 0.05M ammonium sulfate, 0.05M Bis-Tris, 30% v/v 
pentaerythritol ethoxylate (15/4 EO/OH). Crystals were cryoprotected by adding glycerol directly 
to drops to a final concentration of 20% and then looped and cryopreserved in liquid nitrogen. 
 
X-ray diffraction data were collected at the Stanford Synchrotron Radiation Lightsource (SSRL) 
beamline 12-2 on a Pilatus 6M pixel detector (Dectris). Data from single crystals were indexed 
and integrated in XDS (Kabsch, 2010) and merged using AIMLESS in CCP4 (Winn et al., 2011) 
(Table S1). The C022-RBD structure was solved by molecular replacement in PHASER (McCoy 
et al., 2007) using unmodified RBD coordinates (PDB 7K8M) and coordinates from C102 Fab 
(PDB 7K8M) after trimming heavy chain and light chain variable domains using Sculptor 
(Bunkóczi and Read, 2011) as search models. Coordinates were refined with phenix.refine from 
the PHENIX package ver. 1.17.1 (Adams et al., 2010) and cycles of manual building in Coot (ver 
0.8.9.1) (Emsley et al., 2010) (Table S1).  
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Cryo-EM Sample Preparation 
C118 Fab-S trimer complex was assembled by incubating purified SARS-CoV-2 S trimer at a 
1.2:1 molar excess of purified Fab per S protomer at RT for 30 min. 17 uL of complex was 
mixed with 0.8uL of a 0.5% w/v F-octylmaltoside solution (Anatrace) and then 3µL were 
immediately applied to a 300 mesh, 1.2/1.3 AuUltraFoil grid (Electron Microscopy Sciences) that 
had been freshly glow discharged for 1 min at 20mA using a PELCO easiGLOW (Ted Pella). 
The grid was blotted for 3.5s with Whatman No. 1 filter paper at 22°C and 100% humidity then 
vitrified in 100% liquid ethane using a Mark IV Vitrobot (FEI) and stored under liquid nitrogen. 
 
Cryo-EM data collection and processing 
Single-particle cryo-EM data were collected for the C118-S trimer complex as previously 
described (Barnes et al., 2020a). Briefly, for the C118-S trimer complex, micrographs were 
collected on a Talos Arctica transmission electron microscope (Thermo Fisher) operating at 200 
kV using a 3x3 beam image shift pattern with SerialEM automated data collection software 
(Mastronarde, 2005). Movies were obtained on a Gatan K3 Summit direct electron detector 
operating in counting mode at a nominal magnification of 45,000x (super-resolution 0.4345 
Å/pixel) using a defocus range of −0.7 to −2.0 μm. Movies were collected with an 3.6 s exposure 
time with a rate of 13.5 e-/pix/s, which resulted in a total dose of ~60 e-/Å2 over 40 frames. The 
2,970 movies were patch motion corrected for beam-induced motion including dose-weighting 
within cryoSPARC v3.1 (Punjani et al., 2017) after binning super resolution movies by 2 (0.869 
Å/pixel). The non-dose-weighted images were used to estimate CTF parameters using Patch 
CTF in cryoSPARC, and micrographs with poor CTF fits and signs of crystalline ice were 
discarded, leaving 2,487 micrographs. Particles were picked in a reference-free manner using 
Gaussian blob picker in cryoSPARC (Punjani et al., 2017). An initial 923,707 particle stack was 
extracted, binned x4 (3.48 Å/pixel), and subjected to ab initio volume generation (4 classes) and 
subsequent heterogeneous refinement. The 3D classes that showed features for a Fab-S trimer 
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complex were 2D classified to identify class averages corresponding to intact S-trimer 
complexes with well-defined structural features. This routine resulted in a new particle stack of 
110,789 particles, which were unbinned (0.836 Å/pixel) and re-extracted using a 432 box size. 
Particles were then moved to Relion v3.1 (Zivanov et al., 2018), for further 3D classification 
(k=6)., which revealed two distinct states of the C118-S trimer complex.  
 
Particles from state 1 (53,728 particles) and state 2 (31,422 particles) were separately refined 
using non-uniform 3D refinement imposing either C3 or C1 symmetry in cryoSPARC, 
respectively, to final resolutions of 3.4 Å and 4.5 Å according to the gold-standard FSC (Bell et 
al., 2016), respectively. To improve features at the C118-RBD interface, particles from State 1 
were symmetry expanded and classified for a focused, non-uniform 3D local refinement in 
cryoSPARC. A soft mask was generated around the C118 VHVL – RBD domains (5-pixel 
extension, 10-pixel soft cosine edge) for local refinements. These efforts resulted in a modest 
improvement in the RBD-C118 Fab interface (Figure S6B), with an overall resolution of 3.7 Å 
according to the gold-standard FSC. 
 
Cryo-EM Structure Modeling and Refinement 
Initial coordinates were generated by rigid-body docking reference structures into cryo-EM 
density using UCSF Chimera (Goddard et al., 2007). The following coordinates were used: 
SARS-CoV-2 S 6P trimer: PDB 7K4N (mutated to include 6P mutations), PDB 7BZ5, and C118 
Fab variable domains: this study. These initial models were then refined into cryo-EM maps 
using one round of rigid body refinement, morphing and real space refinement in Phenix 
(Adams et al., 2010). Sequence-updated models were built manually in Coot (Emsley et al., 
2010) and then refined using iterative rounds of refinement in Coot and Phenix (Adams et al., 
2010). Glycans were modeled at possible N-linked glycosylation sites (PNGSs) in Coot using 
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‘blurred’ maps processed with a variety of B-factors (Terwilliger et al., 2018). Validation of model 
coordinates was performed using MolProbity (Chen et al., 2010) and is reported in Table S3. 
 
Structure Analyses 
Interacting residues were determined using PDBePISA (Krissinel and Henrick, 2007) for the 
C118 and C022 epitopes using the following criteria: Potential H-bonds were assigned using a 
distance of <3.6A ̊ and an A-D-H angle of >90˚, and the maximum distance allowed for a van 
der Waals interaction was 4.0A ̊. H-bonds assigned for the C022-RBD complex should be 
considered tentative due to the relatively low resolution of the structure (3.2Å). Epitope patches 
for other antibodies in Figure 4A were defined as residues containing an atom within 4Å of the 
partner protein as determined in PyMOL (Schrödinger, 2011). Buried surface areas (BSAs) 
were determined with PDBePISA (Krissinel and Henrick, 2007) using a 1.4A ̊ probe. Structure 
figures were made using PyMOL ver. 2.3.5 (Schrödinger, 2011) or UCSF Chimera ver. 1.14 
(Goddard et al., 2018). Fab-RBD-ACE2 complex figures (Figure 2E) were made by aligning 
RBD Ca atoms of Fab-RBD (this study and PDBs 6W41 and 6ZCZ) and RBD-ACE2 structures 
(PDB 6M0J). As density at position N357RBD for our C118-SARS RBD structure precluded 
building of the glycan, it was modeled (Figure 2A) by aligning Ca atoms of residues 353-371 of 
SARS-CoV spike-S230 structure (PDB 6NB6, chain E) and overlaying the glycan at N357RBD 
from the SARS-CoV spike on the RBD model of the C118-RBD crystal structure. Sequence 
alignments were done using the MUSCLE server (https://www.ebi.ac.uk/Tools/msa/muscle/) 
(Edgar, 2004). Secondary structure was defined as described in (Huo et al., 2020). 
 
To predict whether intra-spike crosslinking by a single IgG binding to a spike trimer might be 
possible, we measured the distance between residue 222HC Ca atoms in the CH1 domains of 
adjacent Fabs in Fab-S structures as previously described (Barnes et al., 2020a). This distance 
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was compared to analogous distances in crystal structures of intact IgGs (42Å, PDB 1HZH; 
48Å, PDB 1IGY; 52Å, PDB 1IGT). We accounted for potential influences of crystal packing in 
intact IgG structures, flexibility in the VH-VL/CH1-CL elbow bend angle, and uncertainties in CH1-
CL domain placement in Fab-S cryo-EM structures, by setting a cut-off of ≤65Å for this 
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Table S1: Crystallographic data collection and validation statistics for C118-SARS RBD 
and C022-SARS2 RBD (related to Figure 2) 
 
Table S2. Buried Surface Area (related to Figure 3) 
 
Table S3. Cryo-EM data collection and refinement statistics for C118-S complex structure 
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Table S1: Crystallographic data collection and validation statistics for C118-SARS RBD 
and C022-SARS2 RBD. (Related to Figure 2) 
 
 C118 Fab – SARS-CoV RBD C022 Fab – SARS-CoV-2 RBD 
PDB ID AAAA BBBB 
Data collectiona,b   
Space group P21 P61 
Unit cell (Å) 92.9, 90.0, 93.9 178.4 178.4 247.3 
    α, β, γ (°) 90.0, 113.3, 90.0 90.0 90.0 120.0 
Wavelength (Å) 0.980 0.980 
Resolution (Å) 46.6 -2.70 (2.80-2.70) 44.6-3.20 (3.32-3.20) 
Unique Reflections 37504 (3085) 73262 (7338) 
Completeness (%) 95.7 (79.5) 99.5 (96.9) 
Redundancy 3.4 (2.9) 10.3 (9.8) 
CC1/2 (%) 99.8 (91.8) 99.8 (27.7) 
<I/sI> 13.14 (2.27) 12.87 (0.56) 
Rmerge (%) 6.22 (40.1) 16.4 (492) 
Rpim (%) 3.96 (28.0) 5.36 (165) 
Wilson B-factor (Å2) 59.53 125.06 
   
Refinement and Validation   
Resolution (Å) 2.70 3.20 
Number of atoms 9582 19802 
     Protein 9516 19696 
     Ligand 66 106 
     Waters 0 0 
Rwork/Rfree (%) 19.2/24.1 18.8/23.1 
R.m.s. deviations   
     Bond lengths (Å) 0.009 0.010 
     Bond angles (°) 1.16 1.23 
MolProbity score 1.96 2.04 
Clashscore (all atom) 7.61 8.67 
Poor rotamers (%) 1.71 1.77 
Ramachandran plot   
     Favored (%) 94.60 94.36 
     Allowed (%) 5.07 5.28 
     Disallowed (%) 0.33 0.36 
Average B-factor (Å2) 63.16 124.1 
a Data collected on 12-2 beamline at the Stanford Synchrotron Radiation Lightsource (SSRL). 
b Numbers in parentheses correspond to the highest resolution shell.  
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Table S2. Buried Surface Area (Related to Figure 4) 
Interface Buried Surface Area (Å2) 





COVA1-16 Fab/  
SARS2 RBD 
PDB this study this study PDB 6W41 PDB 7JMW 
Heavy Chain 
Paratope 750 769 593 673 
FWRH1 0 12 4 0 
CDRH1 197 218 271 109 
FWRH2 0 0 0 0 
CDRH2 92 3 113 0 
FWRH3 0 0 3 0 
CDRH3 461 537 202 564 
FWRH4 0 0 0 0 
Light Chain 
Paratope 272 200 432 154 
FWRL1 0 0 0 0 
CDRL1 0 1 239 0 
FWRL2 4 48 50 34 
CDRL2 121 20 62 0 
FWRL3 147 130 28 120 
CDRL3 0 0 0 0 
FWRL4 0 0 0 0 
Total Paratope 1022 969 1025 827 
Heavy Chain 
Epitope 656 704 593 628 
Light Chain Epitope 292 202 398 153 
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Table S3. Cryo-EM data collection and refinement statistics for C118-S complex structure 




















Refined particles 53,728 31,422
Symmetry imposed C3 C1
Nominal Map Resolution (Å)
FSC 0.143 (unmasked/masked) 4.4/3.4 7.7/4.5
FSC 0.143 local (unmasked/masked) 4.8/3.7 NA
Refinement and Validation





Map sharpening B-factor 88
R.m.s. deviations
Bond lengths (Å) 0.01
Bond angles (˚) 0.81
MolProbity score 2.56
Clashscore (all atom) 16.5
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Figure S1. Epitopes of class 1 – class 4 anti-RBD antibodies (related to Figures 1 and 2) 
(A) SARS-CoV-2 RBD surface representation (grey) with N343 glycan (teal). The ACE2 binding 
site is represented by a green dashed line. 
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(B) SARS-CoV-2 RBD surface representation (grey) with overlaid bound models of VHVL of 
antibodies for class 1 (C102, green, PDB: 7K8M), class 2 (C144, purple, PDB: 7K90), Class 3 
(S309, brown, 7JMX), and class 4 (CR3022, orange, PDB: 6W41).  
(C) SARS-CoV-2 surface representation with overlay of bound C118 Fab (blue), C022 Fab 
(red), and CR3022 Fab (orange, PDB: 6W41).  
(D) SARS-CoV-2 RBD surface representation (grey) at 45˚ angle from previous panels. Dotted 
outlines show epitopes of C102 (green), C022 (red), C118 (blue), and CR3022 (orange) 
mapped onto SARS-CoV-2 RBD.  
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Figure S2. Binding and Neutralization of SARS-CoV-2 RBD or pseudoviruses carrying 
spike amino acid substitutions as well as other sarbecovirus pseudoviruses by C118 and 
C022 (related to Figure 1).  
(A) Left: Cartoon model of SARS-CoV-2 RBD (RBD from C022-RBD structure) showing 
locations of point mutations as red spheres and the N343RBD N-glycan as teal sticks. Right: 
Comparison of binding of the indicated monoclonal IgGs to RBD mutants from ELISA data 
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shown as AUC values normalized to antibody binding to ‘wt’ SARS-CoV-2 RBD. Data presented 
are normalized mean AUC values from two independent experiments. 
(B-C) Normalized relative luminescence values for cell lysates of HT1080ACE2 cells 48h after 
infection with SARS-CoV-2 pseudovirus carrying indicated spike variants in the presence of 
increasing concentrations of monoclonal IgGs C118 (B) and C022 (C). The mutants represented 
substitutions found in circulating SARS-CoV-2 sequences with frequencies >0.01% in GISAID 
(Shu and McCauley, 2017). Mean and standard deviation of two experiments, each performed 
in duplicate (n=4), is shown.  
(D) Half-maximal inhibitory concentrations (IC50) calculated from the neutralization curves in 
panels B and C for monoclonal IgGs C022 and C118 for neutralization of ‘wt’ (D614 S trimer) 
and the indicated mutant SARS-CoV-2 S pseudotyped viruses, as well as other sarbecovirus 
pseudoviruses. IC50 values are means of 2 independent experiments. Colors indicate IC50 
ranges, as indicated. The E484K substitution was constructed in an R683G (furin cleavage site 
mutant) background to increase infectivity (Muecksch et al., 2021).  
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Figure S3. SPR-based competition experiment.  
SARS-CoV-2 RBD was coupled to a biosensor chip using primary amine chemistry. An IgG was 
injected first (seconds 0-600). Seconds 600 - 730 represent the delay required to switch 
samples for a subsequent injection. From seconds 730 – 1030, soluble ACE2 was injected. 
























C118 IgG then ACE2!RBD
C022 IgG then ACE2!RBD
CR3022 IgG then ACE2!RBD
C144 IgG then ACE2!RBD
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   FWR1             CDRH1        FWR2         CDRH2 
C118 VH        QVQLVESGGGVVQPGRSLRLSCAASGFTFSN--YAMHWVRQAPGKGLEWVAVISYDGSNKY     
C022 VH        QVQLQESGPGLVKPSETLSVTCTVSGGSISSSRYYWGWIRQPPGKGLEWIGSIYYSG-STY     
COVA1-16 VH    QVQLVQSGAEVKKPGASVKVSCKASGYTFTS--YYMHWVRQAPGQGLEWMGIINSSGGSTS    
          L    **** :**  : :*. :: ::* .** :::.  *   *:**.**:****:. *  .* .. 
 
                               FWR3                         CDRH3                                             
C118 VH        YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCASGYTGY----DYFVRGDYYGLDV 
C022 VH        YNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHAAAYYDRSGYYF-IEYF--QH 
COVA1-16 VH    YAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARPPRNYYDRSGYYQRAEYF--QH 





                         FWR1              CDRL1       FWR2        CDRL2 
C118 VL         QPVLTQSPSA-SASLGASVKLTCTLSSGHSSYAIAWHQQQPEKGPRYLMKLNTDGSHSKGDG 
C022 VL         DIQMTQSPSTLSASVGDSVTITCRASQSISSW-LAWYQQKPGKAPKLLIY----KASSLESG 
COVA1-16 VL     DIQLTQSPSSLSASVGDRVTITCQASQDISNY-LNWYQQRPGKAPKLLIY----DASNLETG 
          L     :  :*****: ***:*  *.:**  *.. *.: : *:**.* *.*. *:      : .   * 
 
                               FWR3              CDRL3                       
C118 VL         IPDRFSGSSSGAERYLTISSLQSEDEADYYCQTWGTGILVFGGGTKLTVLLGQPKAAP 
C022 VL         VPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNNYRYTFGQGTKLEI--KRTVAAP 
COVA1-16 VL     VPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNPPLTFGGGTKLEI--KRTVAAP 




                                   IGHD3-22                       IGHJ1            
Germline                         ATTACTATGATAGTAGTGGTTATTA       GCTGAATACTTCCAGCACTGG                   
COVA1-16      TGTGCGAGGCCCCCTCGAAATTACTATGATAGGAGTGGTTATTATCAGAGGGCTGAATACTTCCAGCACTGG 
C022        CTGTGCGAGACATGCGGCAGCA-TACTATGATAGAAGTGGTTATTATTTCATC---GAATACTTCCAGCACTGG 
 
Figure S4. Comparison of C022, C118, and COVA1-16 VHVL sequences (related to Figure 
3) 
(A,B) Alignment of C118, C022, and COVA1-16 (A) VH and (B) VL domains. Framework regions 
(FWRs) and complementarity determining regions (CDRs) assigned using the IMGT definition 
(Lefranc et al., 2015). Conserved residues (*), residues with similar properties (:), residues with 
weakly similar properties (.).  
(C) Alignment of portions of the C022 and COVA1-16 VH domain nucleotide sequences to 
germline gene segment sequences for IGHD3-22 (sand) and IGHJ1 (teal).  
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Figure S5. Comparison of C022 and COVA1-16 antibody binding 
(A) Cartoon representation of superposition of RBDs from C022-RBD and COVA1-16-RBD 
(PDB 7JMW) crystal structures aligned by their Ca atoms. 
(B) SARS-CoV-2 RBD cartoon model showing differences between C022 (red) and COVA1-16 
(purple) epitopes. 
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(C,D) Interacting residues of SARS-CoV-2 RBD with the CDRH1 regions from (D) C022 Fab 
and (E) COVA1-16 Fab (PDB 7JMW). Colors: Oxygens (red), nitrogens (blue). Carbon atoms of 
critical arginines from each paratope are highlighted in yellow. 
(E) Alignment of CDRH3 amino acid sequences for C022 and COVA1-16 and germline-encoded 
amino acids derived from IGD3-22 (mauve) and IGJ1 (blue) gene segments. Identities between 
C022 or COVA1-16 with IGHD3-22 and IGHJ1 amino acid sequences shown as shaded boxes 
and residues within the CDRH3 loop are green.  
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Figure S6. Details for cryo-EM C118-S reconstructions (related to Figure 5) 
(A) C118-S 6P representative micrograph (top) and 2D class averages (bottom).  
(B) Data processing pipeline for C118-S structure and focused refinement of C118-RBD portion 
of the structure.  
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(C) Gold Standard FSC for final reconstruction of C118-S reconstructions. Resolutions at 
FSC=0.143 are shown for each volume.  
(D) Local resolution estimates for C118-S map and C118-RBD focused map calculated in 
cryoSPARC.  
(E) Ribbon representation of C118-RBD rigid body-refined model into cryoEM density contoured 
at 8s (gray mesh).  
(F) Overlay of C118-RBD (SARS-CoV-2) from Fab-S cryo-EM structure (blue and gray cartoon) 
and C118-RBD (SARS-CoV) (green and light gray). CDRH3 interactions are highlighted. 
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